6
Views
3
CrossRef citations to date
0
Altmetric
Original Article

An Adolescent Case of Retroperitoneal Pure Choriocarcinoma: Successful Treatment with MCNU-Containing High-Dose Chemotherapy Followed by Autologous Bone Marrow Transplantation after Multiple Brain Metastases

, , &
Pages 167-171 | Received 28 Mar 1995, Accepted 06 Jun 1995, Published online: 09 Jul 2009

References

  • Ablin A, Isaacs H I. Germ cell tumors. Principles and Practice of Pediatric Oncology, PA Pizzo, DG Poplack. J.B. Lippincott Co., Philadelphia 1989; 867–887
  • Mackay E N, Sellers A H. A statistical review of malignant testicular tumors based on the experience of the Ontario Foundation Clinics, 1938–1961. Can Med Assoc J. 1966; 94: 889–899
  • Williams S D, Birch R, Einhorn L H. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etopside. N Engl J Med. 1987; 316: 1435–1440
  • Nicols C R, Andersen J, Lazarus H M. High-dose carboplatin and etopside with autologous bone marrow transplantation in refractory germ cell cancer: An Eastern Cooperative Oncology Group Protocol. J Clin Oncol. 1992; 10: 558–563
  • Motzer R J, Gulati S C, Crown J P. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. Cancer 1992; 69: 550–556
  • Logothetis C J, Samuels M L, Trindade A. The management of brain metastases in germ cell tumors. Cancer 1982; 49: 12–18
  • Levin V, Freeman D, Landahl H. Permeability characteristics of brain adjacent to tumor in rats. Arch Neurol. 1975; 32: 785–791
  • Harada K, Kiya K, Kobayashi M, Takeda T. Pharmacokinetics of a new water-soluble nitrosourea (MCNU) on brain tumors. Cancer Chemother. 1981; 8: 735–742
  • Murphy B R, Breeden E S, Donohue J P. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol. 1993; 11: 324–329
  • Takaue Y, Watanabe T, Hoshi Y. Effectiveness of high-dose MCNU therapy and hematopoietic stem cell autografts treatment of childhood acute leukemia/lymphoma with high-risk features. Cancer 1991; 67: 1830–1837

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.